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Gender differences in retention and survival on 




There is currently a dearth of  knowledge on gender differences in 
mortality among patients on ART in Africa.
Methods
Using data from the national ART monitoring and evaluation 
system, a survival analysis of  all healthcare workers, teachers, and 
police/army personnel who accessed ART in Malawi by June, 
September and December 2006 respectively, was undertaken. 
Gender differences in survival were analysed using Kaplan-Meier 
estimates and rate ratios were derived from Poisson regression 
adjusting for confounding.
Results
4670 ART patients (49.8% female) were followed up for a median 
of  8.7 months after starting ART. Probability of  death was 
significantly higher for men than women (p<0.001). Controlling 
for age, WHO clinical stage and occupation, men experienced 
nearly 2 times the mortality of  women RR 1.90 [95% CI: 1.57-
2.29]. A higher proportion of  men initiated ART in WHO stage 
4 (p<0.001).
Conclusion
Among healthcare workers, teachers, police/army personnel, men 
have higher mortality on ART than women. Possible reasons 
are unclear but could be biological or because men present for 
ART at a later clinical stage or have poorer adherence to therapy. 
Improving early access to ART may reduce mortality, especially 
among men. A gender difference in adherence to therapy needs 
further investigation.
Introduction
Since the advent of  ART, mortality rates for people living with 
HIV/AIDS have decreased substantially both in resource-
rich1,2 and resource-limited settings3,8with conflicting reports 
about gender-related differences in mortality9-16. Where 
differences have been reported, little is known about the 
reasons.
Identifying whether men and women benefit equally from 
ART and ascertaining the reasons underlying any difference 
could inform strategies designed to address these differences 
and optimise ART delivery. This is especially important in 
resource limited settings like Malawi (where ART scale-up is 
a major focus), and particularly among specific occupational 
sub-groups of  the population who contribute significantly to 
the socio-economic development of  the country and whose 
skill-base continues to be depleted by HIV/AIDS. Previous 
studies have considered the general population rather than 
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specific occupational groups.
Previous studies in Malawi focused on the specific 
occupational groups of  health care workers17 teachers18 army 
19and police personnel20separately reporting outcomes in 
relation to demographic and clinical variables. As the same 
systems of  recording and data collection were used for each 
study, we decided to combine the databases of  the four 
studies to determine whether there is a gender difference 
in mortality among adults receiving ART in Malawi, and to 
explore possible reasons for any difference among healthcare 
workers, teachers, army and police personnel.
Materials and Methods
Ethics Statement
General measures are provided in all ART facilities to 
ensure patient confidentiality, consent for HIV testing, and 
counselling and support for those who receive a positive HIV 
test result. Data for this study did not include any personal 
identifiers and were analysed anonymously. The Malawi 
National Health Science Research Committee provides 
general oversight and approval for the collection and use of  
routine programmatic data for monitoring and evaluation, as 
was the case with this study.
Formal ethical approval was therefore not required from 
the Malawi Research Committee and as such, no application 
was made for ethical approval from either Medecins sans 
Frontieres or The International Union against Tuberculosis 
and Lung Disease.
Background
Malawi is among the poorest countries in sub-Saharan Africa 
with an estimated population of  about 13 million21. Like 
other countries in the region, it has experienced a severe HIV 
epidemic. The national HIV adult prevalence is estimated at 
about 12% with 810,000 adults living with HIV/AIDS 22.
Described previously,23 ART scale-up in Malawi began in June 
2004 utilising a national roll-out programme of  free ART to 
all public-sector facilities. ART scale up in the private sector 
has followed the same process with private treatment offered 
at a subsidised cost. As of  September 2008, there were 170 
facilities in the public health sector and 44 sites in the private 
sector providing ART to over 135,000 patients24.
Patients are eligible for ART if  they are HIV-seropositive, 
understand the implications of  starting ART and either 
present in WHO Clinical Stage 3 or 4 or have a CD4-
lymphocyte count of  250/mm3 or less (irrespective of  
WHO stage)25. Without the equipment to perform CD4-
lymphocyte counts, most clinics use clinical staging alone to 
determine ART eligibility.
Malawi uses a standardised ART approach: use of  one generic 
fixed dose combination of  stavudine (d4T), lamivudine (3TC) 
and nevirapine (NVP). There are two alternative first line 
regimens for patients with serious side effects, substituting 
d4T with zivoudine (AZT) or NVP with efavirenz (EFV). 
Two standard proteinaseinhibitor based second line regimens 
are available for adults and children with drug failure.
A nationally standardised process of  registration, monitoring 
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and reporting of  cases and outcomes is used26. Using one 
master card per patient and one ART register per ART facility23 
patient demographic details, occupation, ART start date and 
WHO stage together with any stage defining conditions at 
ART initiation, are recorded. After starting ART, patients 
are followed up at two weeks and then at monthly intervals 
for clinical assessment and ARV dispensing. Monthly visits 
are recorded on the master card and patient outcomes are 
updated quarterly in the ART register. Standardised follow-
up outcomes are defined as: alive and on ART (patient alive 
and on ART at the facility where he/she is registered); dead 
(patient who has died from any cause while on ART); lost 
to follow-up (patient on ART who has not attended the 
ART clinic for 3 months or longer for no known reason and 
cannot be traced); stopped treatment (patient who is known 
to be alive and has stopped ART for any reason); transferred 
out (patient who has transferred-out permanently to another 
treatment facility). Active follow-up of  patients who default 
is not mandatory due to limited resources but most facilities 
routinely attempt to trace patients who have failed to attend 
their scheduled appointment.
At the end of  every quarter, each facility conducts a cohort 
analysis of  patients newly registered during the quarter and 
of  all patients ever registered at the facility. The Ministry of  
Health’s Department of  HIV and AIDS and its partners 
conduct quarterly supervisory and monitoring visits to all 
public sector ART facilities in the country.
They check the completeness of  the ART registers, cross-
check the data recorded on the patient master cards with 
the data entered in the ART registers and cross-check the 
cohort analysis23. In the private sector a similar supervisory 
and monitoring system is conducted.
Data Collection
During three rounds of  quarterly supervision visits to all 
public and private ART facilities between July 2006 and 
March 2007, individual level patient data were collected 
for the following occupational cohorts: healthcare workers, 
teachers and army/police personnel17,18,19,20. The following 
patient data were transcribed from the ART registers onto 
structured data collection forms: sex, age, date and WHO 
clinical stage at ART initiation together with selected stage 
defining conditions, date and reason for termination of  
observation at the respective facility (alive on ART at end of  
observation, transferred to another facility, stopped treatment 
(‘ART stop’), lost to follow up, death). Observations were 
censored depending on the time of  data collection: healthcare 
workers (30 June 2006); teachers (30 September 2006); army 
and police personnel (31 December 2006).
Data Analysis
Data were double entered in Microsoft Access and analysed 
using STATA version 10. Death was used as the failure event 
for the analysis of  mortality rates. Due to the incomplete 
ascertainment of  deaths and in order to control for 
potentially differential ascertainment of  death by gender, 
a separate analysis was done combining death, ART stop 
and loss to follow-up as the failure event (‘ART drop-out’). 
For the person years denominator, patients were generally 
considered to come under observation at the time of  ART 
initiation. For 718 patients who had initiated ART before 
implementation of  the standard M&E tools in June 2004, 
the 1st of  June 2004 was used as the observation start date, 
but their previous exposure time on ART was accurately 
accounted for in the time at risk. Observations ended at the 
end of  the quarter of  data collection or at the time of  death, 
ART stop, transfer-out to another facility or loss to follow-
up. Twenty-two cases were excluded because the date of  
ART initiation or date of  termination of  observation, were 
inconsistent or incomplete.
Gender was the main exposure of  interest. Age, clinical 
stage at ART initiation, specific stage defining conditions, 
occupation and type of  ART facility were considered as 
potential confounders in the association of  gender with 
mortality and ART drop-out. The strength of  association 
between gender and other background variables was 
measured using the X2 test. Cumulative survival probabilities 
were estimated using the Kaplan-Meier method and survival 
between men and women was compared using the log-rank 
test. Rate ratios were calculated for mortality and ‘ART drop-
out’. Poisson regression models were used to compare rates 
between men and women, adjusting for age and WHO clinical 
stage at ART initiation. P-values were derived from the Wald 
test and 95% confidence intervals for point estimates are 
given throughout.
Results
Characteristics of  the study population and gender 
differences in death
Of  a total of  4692 patients receiving ART between June 2004 
and December 2006, 4670 were included in the analysis. Of  
these, 2346 (50.2%) were men. Women were on average 3 
years younger than men at ART initiation (median age 39 
years for men (interquartile range (IQR) 35-44 years) and 36 
years for women (IQR 32-42 years).
Men initiated ART in clinically more advanced stages than 
women. A total of  731 (31.2%) men and 577 (24.8%) women 
were in WHO clinical stage 4 at ART initiation (p<0.001); 354 
(15.1%) men and 394 (17.0%) women were in stage 1 or 2 
with a CD4 count below 250 cells/μl (Table 1). Clinical stage 
at ART initiation was missing for 37 patients (0.8%). More 
than twice as many men presented with Kaposi’s sarcoma at 
ART initiation (197 men (8.4%) versus 95 women (4.1%), 
p<0.001), but similar proportions of  men and women had 
pulmonary and extra-pulmonary tuberculosis. (Table1). 
Most patients (4413 patients, 94.5%) were from public 
sector clinics, but the proportion of  private sector patients 
was higher among women (37 men (1.6%) versus 88 women 
(3.8%), p<0.0001).
A total of  547 patients died, 20 stopped ART and 288 were 
lost to follow-up in 4,439 person-years of  observation 
(PYO), resulting in a mortality rate of  123.2 per 1000 PYO 
[95% CI, 113.3-134.0] and an ‘ART drop-out’ rate of  192.6 
per 1000 PYO [95% CI, 180.1-206.0]. Mortality was 402.3/ 
1000 PYO [95% CI, 356.7-453.6] in month 0-2 after ART 
initiation, 130.0/ 1000 PYO [95% CI, 135.1-190.5/ 1000 
PYO] in month 3-5, 70.2/ 1000 PYO [95% CI, 56.6-87.0/ 
1000 PYO] in month 6-11 and 59.8/ 1000 PYO [95% CI, 
44.5-80.3/ 1000 PYO] in month 12-17. Table 2 shows that 
mortality and ART drop-out rates declined in a very similar 
fashion after ART initiation.
Median follow-up time was 9.0 months for women (range 
0.03 - 60.5 months) and 8.4 months for men (range 0.03 - 
63.1 months). A total of  341 deaths were recorded in 2171 
PYO among men, resulting in a mortality rate of  157.1/ 
1000 PYO [95%CI, 141.3-174.7/ 1000 PYO]; 206 deaths 
were recorded in 2268 PYO among women, resulting in a 
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mortality rate of  90.8/ 1000 PYO [95%CI: 79.3-104.1]. ART 
drop-out rates were 228.5/ 1000 PYO [95% CI: 209.2-249.5] 
among men and 158.3/ 1000 PYO [95% CI: 142.8-175.6] 
among women. The cumulative probability of  survival at 3, 
6, 12 and 18 months after ART initiation was 90%, 87%, 
83% and 80% for men and 94%, 92%, 90% 88% for women. 
Figure 1 shows the cumulative survival probabilities for 
men and women, illustrating the significantly lower survival 
among men (p<0.001). Mortality rate ratios, comparing men 
with women, were 1.78 [95% CI: 1.39-2.29], 1.37 [95% CI: 
0.97-1.94], 1.99 [95% CI: 1.26-3.14] and 1.84 [95% CI; 0.99-
3.39] at 0-2 months, 3-5 months, 6-11 months and 12-17 
months after ART initiation. Rate ratios for ART drop-out, 
comparing men with women within the respective intervals, 
were 1.58 [95% CI: 1.29-1.94], 1.14 [95% CI: 0.86-1.51], 
1.50 [95% CI: 1.06-2.13] and 1.53 [95%CI: 0.99-2.35]. Table 
2 shows mortality and ART drop-out rates according to 
different background variables. Mortality and ART dropout 
were much higher among patients in stage 4 than stage 3 (RR 
1.98 [95% CI: 1.67-2.37] and RR 1.58 [95% CI: 1.37-1.83] 
respectively). Similarly, Kaposi’s sarcoma was associated 
with over a 2 fold increase in mortality (RR 2.29 [95% CI: 
1.7-2.96] and ART drop out (RR 2.07 [95% CI: 1.67-2.56]). 
Mortality and ART dropout were lower among patients from 
private sector facilities compared to public sector facilities 
(RR 0.15 [95% CI: 0.04-0.60] and RR 0.14 [95% CI: 0.05-
0.44] respectively) although the private sector was a very 
small group (n=125). Similarly mortality and ART drop-out 
were lower among patients who had initiated therapy before 
the roll-out of  free ART (RR 0.38 [95% CI: 0.30-0.47] and 
RR 0.58 [95% CI: 0.49-0.68] respectively). Mortality and 
ART drop-out were similar across different age bands and 
also among the different occupational groups (apart from 
army personnel who had a lower ART drop-out (RR 0.70 
[95% CI: 0.56-0.88]).
Adjusting for different background characteristics showed 
that increased mortality among men was partly explained 
by age, clinical stage and occupation. However, adjusted 
mortality and ART drop-out rates among men were still 
approaching nearly two times that of  women (RR 1.90 [95% 
CI: 1.57-2.29] and RR 1.66 [95% CI: 1.43- 1.92] respectively) 
(Table 2). Adjusted mortality rate ratios, comparing men with 
women, were RR 1.85 [95% CI: 1.42-2.40], RR 1.44 [95% CI: 
1.00-2.06], RR 2.11 [95%CI: 1.33-3.34] and RR 1.94 [95%CI: 
1.04-3.60] at 0-2 months, 3-5 months, 6-11 months and 12-
17 months after ART initiation. There was no statistical 
evidence tha these rate ratios differed across the different 
time intervals (p=0.50).
Discussion
Given the conflicting reports about gender differences in 
mortality of  patients on ART in Africa [13-16], this study 
aimed to determine whether a difference exists and if  so 
possible reasons for it. Whereas previous studies have 
considered this gender difference among individuals on ART 
in the general population, this study focussed on individuals 
on ART from specific occupational groups.
Among healthcare workers, teachers, army and police 
personnel on ART in Malawi, men were found to experience 
higher mortality rates and higher ART drop out rates than 
women after adjusting for age at ART initiation, WHO clinical 
stage and occupation. By considering these two outcomes 
separately, we can assume that if  all defaulters have actually 
died then men have nearly 1.7 times higher mortality than 
women, whereas if  all defaulters have silently transferred to 
another facility and are actually alive on ART elsewhere, then 
men have 1.9 times higher mortality than women.
There are several possible explanations for higher male 
mortality. First, increased mortality among male ART patients 
in our study may have been due or partly due to poorer 
adherence to therapy compared with women. Increased 
mortality among male ART patients in Africa has previously 
been reported, including two reports from Malawi14,15. In one 
of  these reports, the authors suggested that this may be due 
to men having poorer compliance to therapy, as indicated 
by their higher loss to follow-up (18.6% versus 13.0% for 
women)15. However, using loss to follow-up as a measure of  
adherence to therapy is actually misleading. Loss to follow-
up is a measure of  clinic retention and does not necessarily 
reflect adherence to treatment.
For instance, a patient lost to follow-up (i.e. not retained at 
the clinic) might have transferred to another site and might 
be taking his/her drugs perfectly regularly.
Another patient presenting perfectly at each appointment 
might have very poor adherence in terms of  taking his/her 
pills.
Secondly, increased male mortality may be due to men 
starting ART at more advanced stages of  AIDS than 
women. We controlled for level of  disease progression using 
WHO clinical stage but it is likely that there was considerabl 
heterogeneity of  immunological stage within the clinical 
stages. Increased mortality in men may therefore have been 
due to residual confounding from more advanced disease 
at the time of  treatment initiation. However, one finding 
in our study suggests that this may not be the case. Given 
that advanced immunodeficiency is known to be among the 
most important risk factors for early mortality in patients 
on ART,3,6,13,15,27,29 one might hypothesise that if  men are 
experiencing a higher mortality than women due to delayed 
ART initiation, gender differences in early mortality may be 
much greater than differences in later mortality. In fact, across 
different time intervals, mortality rate ratios comparing men 
and women were not statistically different. It must however 
be highlighted that a comparison of  death rates between 
men and women beyond 6 months in this study is difficult 
due to relatively few deaths occurring beyond this time and 
therefore lack of  statistical power to make a comparison.
Nevertheless, delayed ART initiation among men is still an 
issue that probably warrants further examination. Prevention 
of  mother to child transmission (PMTCT) programmes 
have been proposed as an explanation for why some women 
present for ART earlier than men. However, only one woman 
was recorded as starting ART for PMTCT in this current 
study, and we do not think that this explains these particular 
findings. Still, it is likely that women generally access health 
services more frequently than men because of  their children 
(e.g. for child vaccinations, accessing treatment for sick 
children) and this may partly underpin why they generally 
access ART earlier than men. Delayed ART initiation among 
men may also be explained by psychosocial factors such as 
stigma, pride and fear. A previous study from Malawi, also 
reporting a delay in ART initiation among men, suggested 
that this may be due to male dignity and preservation of  
masculinity, a feature of  Malawian culture, supported by 
anecdotal observation and qualitative study15.
Third, there may be a biological sex difference in the 
pharmacology and drug response to ART. In this study, 
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all patients starting ART were started on a fixed dose 
combination of  stavudine, lamivudine and nevirapine. In 
a previous study investigating the pharmacokinetic and 
pharmacodynamic sex differences of  specific antiretroviral 
drugs including lamivudine, women had 1.6 fold higher 
plasma concentrations of  lamivudine triphosphate than men 
and achieved a viral load reduction twice as fast as men [30]. 
Although these data were based on the evaluation of  only 33 
patients, other studies have also reported that women reach 
higher plasma concentrations with a number of  antiretroviral 
drugs compared to men31,32. It is therefore possible that the 
gender difference in mortality found in this study may be 
related to higher drug levels that are achieved in women.
Finally, there may be other factors involved. We have little 
information in Malawi or in other resource-poor settings 
about the comparative rates of  cigarette smoking or 
alcohol consumption between men and women on ART. 
Yet these may affect ART outcomes. There are suggestions 
that smoking may contribute to increased morbidity and 
mortality in HIV-infected populations33 and that alcohol 
may be strongly associated with non-adherence to ART and 
worse virological outcomes34,35. The finding in this study, 
that HIV-infected women on ART tend to live longer than 
HIVinfected men on ART, must also be considered in light 
of  the fact that women also live longer than men in the 
general population. In Malawi, life expectancy for men is 
49 years versus 51 years for women21. Although small, this 
intrinsic sex related biological difference may account for at 
least some of  the gender difference seen in mortality.
The study has several strengths. First, the databases were 
constructed from national surveys using data from a 
rigorously supervised monitoring and evaluation system 
and should therefore be nationally representative of  all 
healthcare workers, teachers, police and army personnel on 
ART in Malawi. Second, by restricting the study to patients 
in specific occupations, important social factors including 
healthcare seeking behaviour and socio-economic status 
should have been controlled for. Third, gender differences in 
mortality and ART drop out were very similar suggesting that 
death ascertainment was non differential between men and 
women, and finally, the defaulter rate in this analysis is lower 
than the national average, because follow-up ascertainment 
was likely better in these occupational cohorts than for the 
total national cohort 36.
There were, however, several limitations of  the study. CD4 
count and viral load measurements were not performed 
at the start and during the course of  ART which may 
otherwise have offered an explanation for the gender 
difference in mortality and could have been used to give a 
clinical indication of  adherence to therapy. There was no 
available data for body mass index, adherence to treatment 
and changes in ART regimen (the analysis being based on 
an ’intention to treat’ analysis) so residual confounding 
from any of  these variables could have meant that the study 
under- or overestimated the gender difference in mortality. 
In addition, data on death were noncause specific so some 
deaths could have been non-HIV related. The study included 
patients who had transferred out; this could potentially have 
led to a duplication of  observation time which would have 
led to an underestimation of  mortality rates.
However since transfer out rates were very small and very 
similar for men and women, the effect of  this is likely to 
be small. Finally, our findings can only be generalised to 
healthcare workers, teachers, army and police personnel in 
Malawi rather than the general population.
Conclusion and recommendations
Among healthcare workers, teachers, police and army 
personnel in Malawi, HIVinfected men on ART experience 
significantly higher mortality than women. This gender 
difference may be due to men starting ART at a later clinical 
stage than women (although there is some evidence to doubt 
this); it may be due to poorer compliance to therapy among 
men than women; it may be biological or due to other factors 
such as cigarette smoking and alcohol.
To improve early access one strategy may be to identify 
patients with advanced clinical disease and implement 
a system to fast track them onto treatment. It has been 
suggested that identification of  these ‘high risk’ patients 
could also be facilitated by other disease programmes such 
as tuberculosis treatment programmes27. With pulmonary 
tuberculosis (PTB) one of  the most common manifestations 
of  WHO stage 3 disease in Malawi (32% of  patients in 
this study who started ART at WHO stage 3 presented 
with PTB), TB treatment programmes are potentially a key 
point of  access to ART services. In Malawi the national TB 
programme works in collaboration with the ART programme 
to identify and refer these patients appropriately. Efforts to 
strengthen this referral process may facilitate earlier access 
to treatment. In addition, using qualitative approaches to 
ascertain why some men delay ART initiation would enable 
appropriate strategies to be deployed to try and encourage 
earlier access.
Secondly, the issue of  adherence to therapy possibly being 
poorer among men also needs further study. Thirdly, if  some 
of  the gender difference in mortality is due to a gender 
difference in the pharmacology and drug response to ART, 
this needs to be verified in future studies first before the 
practical implications of  altering drug dosage according 
to sex are given any due consideration. Fourth, the effects 
of  cigarette smoking and alcohol and other determinants 
in relation to gender should be investigated. Finally, it is 
believed that mortality during screening before people are 
started on ART in Malawi is very high; whether there are 
differences in survival between men and women at this stage 
poses yet another question.
Acknowledgments
The data collected for the healthcare workers, teachers, army 
and police operations studies were supported through an 
anonymous donor and linked to routine supervisor visits 
carried out by the Department of  HIV and AIDS in the 
Malawi Ministry of  Health. The funders had no role in study 
design, data collection and analysis, decision to publish, or 
preparation of  the manuscript.
Authors contributions
Anthony Harries, Erik Schouten and Andreas Jahn were 
involved in the ART monitoring and evaluation over the 
period in this study and participated in data collection. 
Anthony Harries, Erik Schouten, Kelita Kamoto, Sam Phiri 
and Andreas Jahn designed the study. Katie Taylor-Smith, 
Hannock Tweya, Anne Ben-Smith and Andreas Jahn analysed 
and interpreted the data. Katie Taylor-Smith, Hanock
Tweya, Anthony Harries and Andreas Jahn wrote the first 
draft. The second and subsequent drafts were reviewed and 
critically appraised by all co-authors. All authors have seen 
MMJ 22(2) 2010 www.mmj.medcol.mw
53 Gender diffrences
and approved the final draft for submission.
References
1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of  
potent antiretroviral therapy on time to AIDS and death in 
men with known HIV infection duration. Multicenter AIDS 
Cohort Study Investigators. Jama 1998; 280: 1497-1503.
2. CASCADE Collaboration. Survival after introduction of  
HAART in people with known duration of  HIV-1 infection. 
The CASCADE Collaboration. Concerted Action on 
SeroConversion to AIDS and Death in Europe. Lancet 2000: 
355: 1158-1159.
3. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of  
a pilot antiretroviral drug therapy programme in Uganda: 
patients’ response, survival, and drug resistance. Lancet 2002; 
360: 34-40.
4. Wester CW, Kim S, Bussmann H, et al. Initial response to 
highly active antiretroviral therapy in HIV-1C-infected adults 
in a public sector treatment program in Botswana. J Acquir 
Immune Defic Syndr 2005; 40: 336-343.
5. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after 
two years of  providing antiretroviral treatment in Khayelitsha, 
South Africa. Aids 2004; 18: 887- 895.
6. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of  
antiretroviral therapy at primary care sites in Zambia: 
feasibility and early outcomes. Jama 2006: 296: 782- 793.
7. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood 
R. Determinants of  mortality and nondeath losses from an 
antiretroviral treatment service in South Africa: implications 
for program evaluation. Clin Infect Dis 2006; 43: 770-776.
8. Jahn A, Floyd S, Crampin AC, et al. Population-level effect 
of  HIV on adult mortality and early evidence of  reversal 
after introduction of  antiretroviral therapy in Malawi. Lancet 
2008; 371: 1603-1611.
9. Perez-Hoyos S, del Amo J, Muga R, et al. Effectiveness 
of  highly active antiretroviral therapy in Spanish cohorts of  
HIV seroconverters: differences by transmission category. 
Aids 2003; 17: 353-359.
10. Hall HI, McDavid K, Ling Q, Sloggett A. Determinants 
of  progression to AIDS or death after HIV diagnosis, United 
States, 1996 to 2001. Ann Epidemiol 2006; 16: 824-833.
11. Moore AL, Kirk O, Johnson AM, et al. Virologic, 
immunologic, and clinical response to highly active 
antiretroviral therapy: the gender issue revisited. J Acquir 
Immune Defic Syndr 2003; 32: 452-461.
12. d’Arminio A, Sabin CA, Phillips AN, et al. (2004) Cardio 
and cerebrovascular events in HIV-infected persons. Aids 
2004; 18: 1811-1817.
13. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, 
Ferradini L. Generic fixed-dose combination antiretroviral 
treatment in resource-poor settings: multicentric observational 
cohort. Aids 2006; 20: 1163-1169.
14. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of  
highly active antiretroviral therapy in a rural district of  
Malawi: an effectiveness assessment. Lancet 2006; 367: 1335-
1342.
15. Chen SC, Yu JK, Harries AD, et al. Increased mortality 
of  male adults with AIDS related to poor compliance to 
antiretroviral therapy in Malawi. Trop Med Int Health 2008; 
13: 513-519.
16. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and 
causes of  death in adults receiving highly active antiretroviral 
therapy in Senegal: a 7-year cohort study. Aids 2006; 20: 
1181-1189.
17. Makombe SD, Jahn A, Tweya H, et al. A national survey 
of  the impact of  rapid scale-up of  antiretroviral therapy on 
health-care workers in Malawi: effects on human resources 
and survival. Bull World Health Organ 2007; 85: 851-857.
18. Makombe SD, Jahn A, Tweya H, et al. A national survey 
of  teachers on antiretroviral therapy in Malawi: access, 
retention in therapy and survival. PLoS ONE 2007; 2: e620.
19. Banda AC, Makombe SD, Jahn A, et al. Antiretroviral 
therapy in the Malawi defence force: access, treatment 
outcomes and impact on mortality. PLoS ONE 2008; 3: 
e1445.
20. Makombe S, Jahn A, Tweya H, et al. The impact of  
national antiretroviral treatment programme on public 
services in Malawi: access and survival on therapy among 
the police force. Malawi Medical Journal 2008; 20: 23-27.
21. World Health Organization. WHO Statistical Information 
System 2008; http://www.who.int/countries/mwi/en/.
22. National AIDS Commission. HIV and syphilis sero-
survey and national HIV prevalence and AIDS estimates. 
2007. Lilongwe: Malawi Ministry of  Health.
23. Libamba E, Makombe S, Harries AD, et al. Scaling up 
antiretroviral therapy in Africa: learning from tuberculosis 
control programmes - the case of  Malawi. Int J Tuberc Lung 
Dis 2005; 9: 1062-1071.
24. Malawi Ministry of  Health. Antiretroviral therapy in 
the public and private sectors in Malawi: results up to 30th 
September, 2008. Lilongwe: HIV Unit. 2008.
25. Malawi Ministry of  Health. Treatment of  AIDS: 
Guidelines for the use of  antiretroviral therapy in Malawi. 
Second Edition. Lilongwe: HIV Unit. Second Edition. 
2006.
26. Libamba E, Makombe S, Mhango E, et al. Supervision, 
monitoring and evaluation of  nationwide scale-up of  
antiretroviral therapy in Malawi. Bull World Health Organ 
2006; 84: 320-326.
27. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early 
mortality among adults accessing a community-based 
antiretroviral service in South Africa: implications for 
programme design. Aids 2005; 19: 2141-2148.
28. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk 
factors for high early mortality in patients on antiretroviral 
treatment in a rural district of  Malawi. Aids 2006; 20: 2355-
2360.
29. Braitstein P, Brinkhof  MW, Dabis F, et al. Mortality of  HIV-
1-infected patients in the first year of  antiretroviral therapy: 
comparison between low-income and highincomecountries. 
Lancet 2006; 367: 817-824.
30. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. 
Antiviral dynamics and sex differences of  zidovudine and 
lamivudine triphosphate concentrations in HIV-infected
individuals. Aids 2003; 17: 2159-2168.
31. Cressey TR, Lallemant M. Pharmacogenetics of  
antiretroviral drugs for the treatment of  HIV-infected 
patients: an update. Infect Genet Evol 2007; 7: 333-342.
32. Umeh OC, Currier JS. Sex differences in pharmacokinetics 
and toxicity of  antiretroviral therapy. Expert Opin Drug Metab 
Toxicol 2006; 2: 273-283.
Gender diffrences  54
MMJ 22(2) 2010 www.mmj.medcol.mw
33. Marshall MM, McCormack MC, Kirk GD. Effect of  
cigarette smoking on HIV acquisition, progression, and 
mortality. AIDS Education and Prevention 2009; 21: 28-39
34. Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. 
Alcohol use and antiretroviral adherence: review and meta-
analysis. J Acquir Immune Defic Syndr 2009; August 7. (epub 
ahead of  print)
35. Miguez-Burbano MJ, Lewis JE, Fishman J, Asthana D, 
Malow RM. The influence of  different types of  alcoholic 
beverages on disrupting highly active antiretroviral treatment 
(HAART) outcome. Alcohol 2009; 44: 366- 371.
36. Malawi Ministry of  Health. ART in the public and 
private sectors in Malawi: results up to 31st December, 2007. 
Lilongwe: HIV Unit.2008.
MMJ 22(2) 2010 www.mmj.medcol.mw
55 Gender diffrences
Gender diffrences  56
MMJ 22(2) 2010 www.mmj.medcol.mw
Health Organisation; PTB, Pulmonary Tuberculosis; PMTCT, Prevention of Mother to Child Transmission; CI, Confidence interval
D/ PYO = deaths or art drop outs per person years of follow up; Rates are per 1000 person years of follow-up  ref Reference group for rate 
ratios; a Adjusted using Poisson regression for age, occupation, clinical stage and time since starting ART; adjusted rate ratios are only shown 
for the variables found to be associated with the gender difference in mortality
